Aims: Better knowledge of the global metabolic syndrome (MetS) prevalence and its components is a prerequisite to curb the related burden. Methods: We systematically searched PubMed, EMBASE, Web of Knowledge, Africa Journal Online, Global Index Medicus up to May 23, 2021. Prevalence pooling was done with a random-effects meta-analysis. Results: In total, 1,129 prevalence data (28,193,768 participants) were included. The MetS global prevalence varied from 12.5% (95 %CI: 10.2–15.0) to 31.4% (29.8–33.0) according to the definition considered. The prevalence was significantly higher in Eastern Mediterranean Region and Americas and increased with country's level of income. The global prevalence was 45.1% (95 %CI: 42.1–48.2) for ethnic-specific central obesity, 42.6% (40.3–44.9) for systolic blood pressure (BP) ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg, 40.2% (37.8–42.5) for HDL-cholesterol < 1.03 for men or < 1.29 mmol/L for women, 28.9% (27.4–30.5) for serum triglycerides ≥ 1.7 mmol/L, and 24.5% (22.5–26.6) for fasting plasma glucose ≥ 5.6 mmol/L. Conclusions: This study reveals that MetS and its related cardiometabolic components are highly prevalent worldwide. This study calls for more aggressive and contextualized public health interventions to tackle these conditions.
- Metabolic syndrome
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism